InDex Pharmaceuticals AB Completes Patient Recruitment in P3 Ulcerative Colitis Study With Kappaproct
4/8/2013 11:35:35 AM
More...
|
InDex Pharmaceuticals AB Granted Japanese Patent for Novel Treatment of Steroid-Resistant Inflammation
10/24/2012 10:17:21 AM
More...
|
InDex Pharmaceuticals AB Strengthens IP Position for Kappaproct
9/4/2012 11:19:38 AM
More...
|
InDex Pharmaceuticals AB Engages PharmaVentures to Facilitate the Licensing of Kappaproct(R) After Phase IIa Trial Achieves Clinical Endpoints Early
5/18/2009 8:56:11 AM
More...
|
The Day In Review: Sanofi-Aventis (France) (SASY.PA) Adds To Generics Business
3/27/2006 6:38:54 PM
More...
|
InDex Signs $35M Agreement With Serono For Inflammation
10/19/2005 5:10:10 PM
More...
|
Serono (SRA) And Swedish Biotech Company InDex Pharmaceuticals AB Sign Worldwide Agreement To Develop And Commercialize Novel Ulcerative Colitis Treatment
10/19/2005 5:10:07 PM
More...
|